United States - DC Metro Area United States Williams & Connolly LLP

Williams & Connolly is a pre-eminent litigation firm, known for the extensive trial experience of its practitioners. Many of the firm’s 290-plus litigators focus on IP matters in all technical industries, including high-stakes patent litigation on behalf of both patentees and alleged infringers, and proceedings before the US Patent and Trademark Office (USPTO).

Many of these lawyers have technical degrees, are admitted before the USPTO and are former clerks of the US Court of Appeals for the Federal Circuit.

In the pharmaceutical and biotechnology sectors, Pfizer, Eli Lilly, Merck, Genentech/Roche, AstraZeneca and its division MedImmune, Bayer, and Novartis and its division Alcon, all entrust critical patent litigation to the firm, as do brands such as Samsung, Google and Dropbox in the technology sector, and major entities in other industries, such as Petroleum Geo-Services.

Notable cases

  • Represented Bayer in litigation brought by Biogen relating to Betaseron, Bayer’s interferon product for treating multiple sclerosis. The case involves the use of genetic engineering to identify the gene that codes for interferon and to transform bacterial cells with plasmids containing the human DNA sequence to induce the bacteria to produce human interferon or related proteins.
  • Represented AstraZeneca and Amylin in litigation and inter partes reviews involving patents related to exendins – a class of peptides with anti-diabetic properties – including patents that protect AstraZeneca’s Byetta product. The accused products are unreleased anti-diabetes products from a competing brand pharmaceutical company.
  • Represented Bayer in several Hatch-Waxman cases relating to Bayer’s erectile dysfunction drug products Levitra and Staxyn. The patents at issue cover the active ingredient, vardenafil, as well as the orally disintegrating tablet formation used in Staxyn. The district court judge ruled in favour of Bayer regarding the validity of the patents.
  • Represented Samsung in an International Chamber of Commerce arbitration against Nokia relating to standard-essential patents and involving products with billions in revenue. The January 2016 award, which set the royalty amount that Samsung will pay to extend its agreement through 2018, has been hailed as a model of constructive resolution of a licensing dispute.
  • Represented Google in the first evermulti-district patent litigation in the Eastern District of Virginia invalidating all claims of the asserted patent, which was alleged to cover such Google products as YouTube, Google Drive and Google Photos, and persuaded the Patent Trial and Appeal Board (PTAB) to institute an inter partes review of the patent.
  • Represented Pfizer in connection
    with district court and inter partes review matters regarding its antibiotic product Tygacil. The cases involved compound, formulation and polymorph patents. In one of the first pharmaceutical inter partes reviews to proceed to trial, we successfully argued to the PTAB that the claims of Pfizer’s patent were valid. The decision was affirmed on appeal.
  • Won a trial verdict in favour of Pfizer regarding Mylan’s attempt to sell a generic version of Pfizer’s cancer drug Sutent. The decision was affirmed on appeal.
  • Represented SenoRx in a patent infringement suit filed by Hologic claiming infringement of patents relating to a device for irradiating the breast following a lumpectomy.
  • Represented Mirowski Family Ventures LLC (MFV), the plaintiff in a complex breach of contract and patent licensing trial against Boston Scientific Corporation, winning a jury award of $309.3 million affirmed on appeal. The complaint sought to recover royalties from sales of implantable cardioverter defibrillators covered by MFV’s patents, and to recapture MFV’s share of the value of two significant patent infringement lawsuits that Boston Scientific had improperly traded away.
  • Represented Genentech and Roche in disputes concerning Genentech’s licensing of PDL BioPharma’s Queen patent portfolio.
  • Represented MedImmune in its challenge to PDL’s Queen patent. The district court invalidated the licensed claim. The case settled with PDL providing MedImmune with a royalty-free licence and returning approximately $100 million in past royalty payments.
  • Represents MedImmune LLC in an action filed by Abbvie, asserting that a patent licensed by Abbvie in connection with its Humira product is invalid. Abbvie asserts that the invalidation of the patent would reduce its royalty obligations in connection with the sale of Humira.

In addition to English, our patent litigators conduct business in multiple languages, including French, Hebrew and Spanish.

Main address

725 12th Street NW
Washington DC 20005
United States

Contact details

E: aperlman@wc.com
T: +1 202 434 5000
F: +1 202 434 5029
W: www.wc.com

Professional contacts

Adam L Perlman, Partner
E: aperlman@wc.com

Thomas HL Selby, Partner
E: tselby@wc.com

Sample client list

  • Alcon
  • AstraZeneca/MedImmune
  • Bayer
  • Eli Lilly
  • Google
  • Merck
  • Pfizer
  • Roche/Genentech
  • Samsung

Recommended individuals at this firm


Register for more free content

  • Read more IAM blogs and articles
  • Receive the editor's weekly review by email
Register now  
Issue 89